{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:20:21Z","timestamp":1775744421627,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-026-04049-w","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T19:14:47Z","timestamp":1772565287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrative multi-omics analysis reveals metabolic dysfunction signatures as critical determinants of prostate cancer prognosis and immunosuppressive microenvironments"],"prefix":"10.1186","volume":"31","author":[{"given":"Xiangqian","family":"Nie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenlin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Decai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"1","key":"4049_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024 [published correction appears in CA Cancer J Clin. 2024 Mar-Apr;74(2):203. doi: 10.3322\/caac.21830]. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4049_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479\u201399.","journal-title":"Annu Rev Med"},{"key":"4049_CR3","doi-asserted-by":"publisher","first-page":"108255","DOI":"10.1016\/j.pharmthera.2022.108255","volume":"238","author":"BR Alabi","year":"2022","unstructured":"Alabi BR, Liu S, Stoyanova T. Current and emerging therapies for neuroendocrine prostate cancer. Pharmacol Ther. 2022;238:108255.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"4049_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-021-01061-x","volume":"14","author":"D Teyssonneau","year":"2021","unstructured":"Teyssonneau D, Margot H, Cabart M, et al. Prostate cancer and PARP inhibitors: progress and challenges. J Hematol Oncol. 2021;14(1):51.","journal-title":"J Hematol Oncol"},{"issue":"6487","key":"4049_CR5","doi-asserted-by":"publisher","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","volume":"368","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473.","journal-title":"Science"},{"key":"4049_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.semcancer.2020.12.002","volume":"82","author":"C Peitzsch","year":"2022","unstructured":"Peitzsch C, Gorodetska I, Klusa D, et al. Metabolic regulation of prostate cancer heterogeneity and plasticity. Semin Cancer Biol. 2022;82:94\u2013119.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"4049_CR7","first-page":"189005","volume":"1878","author":"C Zhang","year":"2023","unstructured":"Zhang C, Wang K, Wang H. Adenosine in cancer immunotherapy: taking off on a new plane. Biochimica et Biophysica Acta (BBA). 2023;1878(6):189005.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"5","key":"4049_CR8","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s11914-021-00695-7","volume":"19","author":"J Whitburn","year":"2021","unstructured":"Whitburn J, Edwards CM. Metabolism in the tumour-bone microenvironment. Curr Osteopor Rep. 2021;19(5):494\u20139.","journal-title":"Curr Osteopor Rep"},{"issue":"1","key":"4049_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","volume":"16","author":"HR Jin","year":"2023","unstructured":"Jin HR, Wang J, Wang ZJ, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. 2023;16(1):103.","journal-title":"J Hematol Oncol"},{"issue":"17","key":"4049_CR10","doi-asserted-by":"publisher","first-page":"8322","DOI":"10.7150\/thno.62378","volume":"11","author":"Z Li","year":"2021","unstructured":"Li Z, Sun C, Qin Z. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. 2021;11(17):8322\u201336.","journal-title":"Theranostics"},{"issue":"5","key":"4049_CR11","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3390\/cells11050896","volume":"11","author":"TY Chia","year":"2022","unstructured":"Chia TY, Zolp A, Miska J. Polyamine immunometabolism: central regulators of inflammation, cancer and autoimmunity. Cells. 2022;11(5):896.","journal-title":"Cells"},{"issue":"1","key":"4049_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30(1):36\u201350.","journal-title":"Cell Metab"},{"issue":"1","key":"4049_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12944-023-01804-4","volume":"22","author":"T Zhai","year":"2023","unstructured":"Zhai T, Dou M, Ma Y, et al. Lipid metabolism-related miRNAs with potential diagnostic roles in prostate cancer. Lipids Health Dis. 2023;22(1):39.","journal-title":"Lipids Health Dis"},{"key":"4049_CR14","doi-asserted-by":"publisher","first-page":"108323","DOI":"10.1016\/j.compbiolchem.2024.108323","volume":"115","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Peng Y, Gao Y, et al. Identification and dissection of prostate cancer grounded on fatty acid metabolism-correlative features for predicting prognosis and assisting immunotherapy. Comput Biol Chem. 2025;115:108323.","journal-title":"Comput Biol Chem"},{"key":"4049_CR15","doi-asserted-by":"publisher","first-page":"1582992","DOI":"10.3389\/fimmu.2025.1582992","volume":"16","author":"W Li","year":"2025","unstructured":"Li W, Wei X, Yu Y, et al. Landscape analysis of matrix metalloproteinases reveals key prognostic markers for prostate cancer. Front Immunol. 2025;16:1582992.","journal-title":"Front Immunol"},{"key":"4049_CR16","doi-asserted-by":"publisher","first-page":"1275461","DOI":"10.3389\/fimmu.2023.1275461","volume":"14","author":"Y Sun","year":"2023","unstructured":"Sun Y, Liu L, Fu Y, et al. Metabolic reprogramming involves in transition of activated\/resting CD4 memory T cells and prognosis of gastric cancer. Front Immunol. 2023;14:1275461.","journal-title":"Front Immunol"},{"issue":"5","key":"4049_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"key":"4049_CR18","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"issue":"1","key":"4049_CR19","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1038\/s41467-022-33780-1","volume":"13","author":"HY Wong","year":"2022","unstructured":"Wong HY, Sheng Q, Hesterberg AB, et al. Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. Nat Commun. 2022;13(1):6036.","journal-title":"Nat Commun"},{"issue":"7683","key":"4049_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature24673","volume":"552","author":"G Germano","year":"2017","unstructured":"Germano G, Lamba S, Rospo G, et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature. 2017;552(7683):116\u201320.","journal-title":"Nature"},{"issue":"1","key":"4049_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.","journal-title":"Genome Med"},{"issue":"1","key":"4049_CR22","doi-asserted-by":"publisher","first-page":"100336","DOI":"10.1016\/j.esmoop.2021.100336","volume":"7","author":"M Palmeri","year":"2022","unstructured":"Palmeri M, Mehnert J, Silk AW, et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2022;7(1):100336. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100336.","journal-title":"ESMO Open"},{"issue":"23","key":"4049_CR23","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3390\/cells13231958","volume":"13","author":"IM Mokhosoev","year":"2024","unstructured":"Mokhosoev IM, Astakhov DV, Terentiev AA, Moldogazieva NT. Human cytochrome P450 cancer-related metabolic activities and gene polymorphisms: a review. Cells. 2024;13(23):1958. https:\/\/doi.org\/10.3390\/cells13231958.","journal-title":"Cells"},{"issue":"1","key":"4049_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","volume":"35","author":"A Prelaj","year":"2024","unstructured":"Prelaj A, Miskovic V, Zanitti M, et al. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. Ann Oncol. 2024;35(1):29\u201365.","journal-title":"Ann Oncol"},{"issue":"7","key":"4049_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41585-019-0193-3","volume":"16","author":"SL Goldenberg","year":"2019","unstructured":"Goldenberg SL, Nir G, Salcudean SE. A new era: artificial intelligence and machine learning in prostate cancer. Nat Rev Urol. 2019;16(7):391\u2013403.","journal-title":"Nat Rev Urol"},{"key":"4049_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70149","author":"J Zhang","year":"2025","unstructured":"Zhang J, Pan J, Lin J, et al. Prognostic and predictive value of machine learning-based biomarker and pathomics signatures in patients with prostate cancer. Cancer Sci. 2025. https:\/\/doi.org\/10.1111\/cas.70149.","journal-title":"Cancer Sci"},{"key":"4049_CR27","doi-asserted-by":"publisher","first-page":"106856","DOI":"10.1016\/j.compbiomed.2023.106856","volume":"159","author":"JM Marr\u00f3n-Esquivel","year":"2023","unstructured":"Marr\u00f3n-Esquivel JM, Duran-Lopez L, Linares-Barranco A, Dominguez-Morales JP. A comparative study of the inter-observer variability on Gleason grading against deep learning-based approaches for prostate cancer. Comput Biol Med. 2023;159:106856.","journal-title":"Comput Biol Med"},{"issue":"7","key":"4049_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ccell.2023.05.016","volume":"41","author":"H Wang","year":"2023","unstructured":"Wang H, Li N, Liu Q, et al. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell. 2023;41(7):1345-1362.e9.","journal-title":"Cancer Cell"},{"key":"4049_CR29","doi-asserted-by":"publisher","first-page":"955669","DOI":"10.3389\/fcell.2022.955669","volume":"10","author":"H Zhou","year":"2022","unstructured":"Zhou H, He Q, Li C, et al. Focus on the tumor microenvironment: a seedbed for neuroendocrine prostate cancer. Front Cell Dev Biol. 2022;10:955669.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"4049_CR30","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1038\/s41467-021-25624-1","volume":"12","author":"S Taavitsainen","year":"2021","unstructured":"Taavitsainen S, Engedal N, Cao S, et al. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nat Commun. 2021;12(1):5307.","journal-title":"Nat Commun"},{"issue":"6","key":"4049_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12032-018-1144-1","volume":"35","author":"MH Townsend","year":"2018","unstructured":"Townsend MH, Robison RA, O\u2019Neill KL. A review of HPRT and its emerging role in cancer. Med Oncol. 2018;35(6):89.","journal-title":"Med Oncol"},{"issue":"1","key":"4049_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13046-024-03184-8","volume":"43","author":"P Geng","year":"2024","unstructured":"Geng P, Ye F, Dou P, et al. HIF-1\u03b1-HPRT1 axis promotes tumorigenesis and gefitinib resistance by enhancing purine metabolism in EGFR-mutant lung adenocarcinoma. J Exp Clin Cancer Res. 2024;43(1):269.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4049_CR33","doi-asserted-by":"publisher","first-page":"112567","DOI":"10.1016\/j.yexcr.2021.112567","volume":"403","author":"MH Townsend","year":"2021","unstructured":"Townsend MH, Bennion KB, Bitter EE, Felsted AM, Robison RA, O\u2019Neill KL. Overexpression and surface localization of HPRT in prostate cancer provides a potential target for cancer specific antibody mediated cellular cytotoxicity. Exp Cell Res. 2021;403(1):112567.","journal-title":"Exp Cell Res"},{"issue":"1","key":"4049_CR34","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1038\/s41467-024-48857-2","volume":"15","author":"J Li","year":"2024","unstructured":"Li J, Deng Z, Soerensen SJC, et al. Ambient air pollution and urological cancer risk: a systematic review and meta-analysis of epidemiological evidence. Nat Commun. 2024;15(1):5116.","journal-title":"Nat Commun"},{"key":"4049_CR35","doi-asserted-by":"publisher","first-page":"108902","DOI":"10.1016\/j.envres.2019.108902","volume":"181","author":"SC Chuang","year":"2020","unstructured":"Chuang SC, Chen HC, Sun CW, et al. Phthalate exposure and prostate cancer in a population-based nested case-control study. Environ Res. 2020;181:108902.","journal-title":"Environ Res"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-026-04049-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:38:42Z","timestamp":1775741922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-026-04049-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4049"],"URL":"https:\/\/doi.org\/10.1186\/s40001-026-04049-w","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"528"}}